Madrigal Doses Oral GLP-1 MGL-2086, Plans 2027 Combo Trials with Rezdiffra
MDGL sits 64% above its 52-week low of $290 on elevated volume (2.2× avg).
Summary
Madrigal has dosed the first patient in a Phase I trial of oral GLP-1 candidate MGL-2086, a key step in building a metabolic pipeline beyond Rezdiffra. The company also outlined plans for three Phase II combination trials in 2027, pairing MGL-2086, ervogastat, and MGL0795 with resmetirom. This follows last week's Q2 report showing Rezdiffra sales of $364.3M and over 49,000 patients on therapy. The pipeline expansion and patent protection into the 2040s strengthen the long-term thesis, though the Phase I readout is still months away.
At the time of this announcement, MDGL was trading at $475.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.8B. The 52-week trading range was $290.00 to $615.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.